Affordable Access

deepdyve-link
Publisher Website

Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.

Authors
  • JamaliMoghadamSiahkali, Saeidreza1
  • Zarezade, Besharat2
  • Koolaji, Sogol3
  • SeyedAlinaghi, SeyedAhmad4
  • Zendehdel, Abolfazl5
  • Tabarestani, Mohammad6
  • Sekhavati Moghadam, Ehsan7
  • Abbasian, Ladan2
  • Dehghan Manshadi, Seyed Ali2
  • Salehi, Mohamadreza2
  • Hasannezhad, Malihe2
  • Ghaderkhani, Sara2
  • Meidani, Mohsen2
  • Salahshour, Faeze8
  • Jafari, Fatemeh2
  • Manafi, Navid9
  • Ghiasvand, Fereshteh10
  • 1 Department of Infectious Diseases, Ziayian Hospital, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 2 Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 3 Department of Cardiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 4 Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 5 Geriatric Department, Ziayian Hospital, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 6 Students Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. , (Iran)
  • 7 Department of Cardiology, Ziayian Hospital, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 8 Department of Radiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 9 Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada. , (Canada)
  • 10 Liver Transplantation Research Center, Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran, Iran. [email protected] , (Iran)
Type
Published Article
Journal
European journal of medical research
Publication Date
Feb 11, 2021
Volume
26
Issue
1
Pages
20–20
Identifiers
DOI: 10.1186/s40001-021-00490-1
PMID: 33573699
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO2) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020.

Report this publication

Statistics

Seen <100 times